Introduction
Over the last few decades, Gram-positive cocci including enterococci have become important nosocomial pathogens. 1 The incidence of Gram-positive cocci with single or multiple resistance to antimicrobial agents such as methicillin-resistant Staphylococcus aureus (MRSA) and penicillin-resistant Streptococcus pneumoniae (PRSP) has increased in both community and nosocomial settings.
Combination antimicrobial therapy for serious enterococcal infections is employed in clinical practice for a variety of reasons, the major one being synergy. The most appropriate treatment for serious enterococcal infections such as endocarditis is based on combinations of a penicillin or a glycopeptide and an aminoglycoside. 2 The increasing frequency of enterococcal strains exhibiting single or multiple resistance traits such as -lactamase production, aminoglycoside resistance and, more recently, the emergence of glycopeptide resistance renders such treatment inappropriate. 1 If -lactams are ineffective, an alternative treatment consists of the synergic vancomycinaminoglycoside combination. However, the recent widespread use of vancomycin has resulted in an increased prevalence of enterococci resistant to glycopeptides (23.9% in USA). Strains of staphylococci with intermediate susceptibility to vancomycin have also been reported. 1 The emergence of high-level aminoglycoside resistance also highlights the need for new combinations of antibiotics.
LY333328 is a new semi-synthetic glycopeptide derived from the N-alkylation of LY264826, a naturally occurring, vancomycin-like drug. In previous studies it has been shown that this new glycopeptide is highly active against Gram-positive bacteria. [3] [4] [5] The present study was carried out to evaluate: (i) the in vitro activity of LY333328 in comparison with other currently available glycopeptides against 637 isolates; and (ii) the potential for in vitro synergy between LY333328 and ciprofloxacin, which, because of its moderate activity against enterococci, can be considered as a good alternative to aminoglycosides against 30 enterococcal strains with different patterns of drug resistance.
Materials and methods

Antimicrobial agents
Antimicrobial agents were kindly supplied as pure powders by their respective manufacturers (LY333328 and vancomycin by Eli Lilly and Co., Indianapolis, IN, USA; ciprofloxacin by Bayer, Milan, Italy; teicoplanin by Aventis, Milan, Italy). Antimicrobial stock solutions were prepared in accordance with NCCLS guidelines.
6 LY333328 was dissolved in water and diluted in cation-adjusted Mueller-Hinton broth (CAMHB) in accordance with the manufacturer's instructions (Eli Lilly and Co.).
Clinical isolates
The in vitro activity of LY333328 was compared with vancomycin and teicoplanin against 637 isolates, which
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Gram-positive cocci are a major cause of nosocomial bacteraemias and are often resistant to most antibiotics. The emergence of enterococci with reduced susceptibility to vancomycin has created an urgent need for novel antibiotics to combat infections associated with these bacteria. In this study the in vitro activity of LY333328 (oritavancin), a semi-synthetic glycopeptide, was evaluated. LY333328 was effective against all strains of staphylococci, streptococci and enterococci tested. A combination of LY333328 and ciprofloxacin was additive for 50% of Enterococcus faecium strains resistant to both vancomycin and ciprofloxacin, and for 100% of vancomycin-susceptible and either ciprofloxacin-susceptible or -resistant strains. 
Susceptibility tests
The MIC, defined as the lowest concentration of antibiotic that yielded no visible growth, and the minimal bactericidal concentration (MBC), defined as the lowest antibiotic concentration that resulted in р0.1% survival in the subculture, were determined by a broth microdilution method in CAMHB according to NCCLS recommendations. Lysed horse blood (5%) was added when streptococci other than enterococci were tested. Plates were incubated at 35°C for 18-24 h for MIC testing, and MBC evaluation was carried out after MIC reading was performed by incubating the plates for a further 24-48 h.
Bacterial resistance to vancomycin and teicoplanin was indicated by an MIC у 16 mg/L. A projected breakpoint of у4 mg/L was adopted for LY333328. Since no NCCLS breakpoints have yet been determined for LY333328, the selection of strains was performed on the basis of susceptibility or resistance to vancomycin.
Assessment of synergy
MICs of each antibiotic were determined by the broth microdilution method; synergy was assessed by a microdilution chequerboard method using CAMHB and repeated twice for each experiment. Fractional inhibitory concentration indexes (⌺FIC) were interpreted as follows: synergy р0.5; additivity ϭ 1.0; antagonism у2, in accordance with the criteria of Krogstad & Moellering. 
Results
S. aureus ATCC 29213 and E. faecalis ATCC 29212 were used as quality control strains. MICs obtained for these strains were within the ranges proposed by NCCLS for all the antimicrobials tested.
The in vitro activity of LY333328, vancomycin and teicoplanin is summarized in Table I Table II . The susceptibility to LY333328 was similar for ciprofloxacin-resistant and vancomycin-resistant and -susceptible strains of enterococci. Table III shows the combined effects of LY333328 and ciprofloxacin against the 30 enterococcal isolates in vitro. The antimicrobial drug combination resulted in synergy for 50% of E. faecium strains resistant to both vancomycin and ciprofloxacin; additivity was observed for all the other strains. There was no antagonistic effect observed with any strain.
Discussion
Vancomycin-resistant enterococci have become a major cause of nosocomial infections. Infections caused by S. aureus with reduced susceptibility to vancomycin and teicoplanin have also been reported recently. 8, 9 One approach to the problem of antimicrobial resistance is the modification of currently known agents to overcome resistance. In the present study LY333328, a semisynthetic glycopeptide derived from a naturally occurring vancomycin-like drug, displayed good in vitro activity against all the Gram-positive microorganisms tested, including those that are resistant to currently available glycopeptides.
LY333328 was highly effective against strains of both MSSA and MRSA, penicillin-susceptible and PRSP, VSE and VRE E. faecium and vancomycin-susceptible E. faecalis. The MIC 90 s obtained are consistent with previous studies in which the inhibitory and bactericidal activities of LY333328 against Gram-positive pathogens were evaluated. 3 The MIC 50 s for LY333328 were similar for all strains of staphylococci, streptococci and enterococci studied. Biavasco et al. 4 have shown that LY333328 was highly active against staphylococci and enterococci and its effects did not vary substantially between the vancomycin-susceptible and -resistant enterococci. LY333328 was effective against vancomycin-susceptible E. faecium and E. faecalis. Thus, the present results complement and extend the previous studies suggesting that LY333328 could be an effective therapeutic alternative to glycopeptides in current use.
In the present study the synergic or additive effects of combined LY333328 and ciprofloxacin on enterococci were also demonstrated by the chequerboard method.
The results of 50% synergy in vancomycin-resistant/ ciprofloxacin-resistant strains of E. faecium and 100% additivity in vancomycin-susceptible/ciprofloxacin-resistant strains of E. faecium and vancomycin-susceptible/ ciprofloxacin-susceptible strains of E. faecalis indicate that this combination could result in a therapeutic advantage for treatment of infections sustained by enterococci with decreased susceptibility to vancomycin. These results are also consistent with those reported by Unal et al., 10 who observed a similar synergy between ciprofloxacin and vancomycin in six E. faecium strains that were resistant to both antimicrobial agents. While they hypothesized that such interactions may be related to a diminished induction of the proteins that mediate resistance for doubly resistant E. faecium, no explanation was given for the absence of synergy in isolates susceptible to vancomycin but resistant to ciprofloxacin. This new glycopeptide compound overcomes the resistance expressed by some enterococcal strains towards the currently available glycopeptides. Results of this study may be of clinical importance for the treatment of those infections caused by enterococci with high-level aminoglycoside resistance as well as vancomycin resistance, but more studies are necessary to confirm these results and to evaluate the clinical efficacy.
